188 related articles for article (PubMed ID: 38037900)
21. Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice.
Wui SR; Kim KS; Ryu JI; Ko A; Do HTT; Lee YJ; Kim HJ; Lim SJ; Park SA; Cho YJ; Kim CG; Lee NG
Vaccine; 2019 Apr; 37(15):2131-2141. PubMed ID: 30827737
[TBL] [Abstract][Full Text] [Related]
22. Tiza-
Vollmer-Raschdorf S; Rashidi-Alavijeh J; Voigt S; Hengel H; Borchardt B; Huzly D; Hüßler EM; In der Schmitten J; Halenius A; Willuweit K; Botzenhardt S; Trilling M; Boettler T; Dehnen D
BMJ Open; 2023 Nov; 13(11):e074461. PubMed ID: 37918931
[TBL] [Abstract][Full Text] [Related]
23. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
24. Immune responses to zoster vaccines.
Levin MJ; Weinberg A
Hum Vaccin Immunother; 2019; 15(4):772-777. PubMed ID: 30676834
[TBL] [Abstract][Full Text] [Related]
25. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
[TBL] [Abstract][Full Text] [Related]
26. LNP-CpG ODN-adjuvanted varicella-zoster virus glycoprotein E induced comparable levels of immunity with Shingrix™ in VZV-primed mice.
Luan N; Cao H; Wang Y; Lin K; Liu C
Virol Sin; 2022 Oct; 37(5):731-739. PubMed ID: 35671982
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
Parikh R; Singer D; Chmielewski-Yee E; Dessart C
Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
[TBL] [Abstract][Full Text] [Related]
29. Cell-Mediated Immune Responses After Administration of the Live or the Recombinant Zoster Vaccine: 5-Year Persistence.
Johnson MJ; Liu C; Ghosh D; Lang N; Levin MJ; Weinberg A
J Infect Dis; 2022 Apr; 225(8):1477-1481. PubMed ID: 34850039
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs.
Kojima S; Iwamoto T; Kobayashi Y; Kato M; Takizawa F; Ida T; Suzuki J; Toda Y; Miyachi K; Iwata A; Furuta S; Ikeda K; Nakajima H
RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388170
[TBL] [Abstract][Full Text] [Related]
31. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
33. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
[TBL] [Abstract][Full Text] [Related]
34. Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.
Dagnew AF; Vink P; Drame M; Willer DO; Salaun B; Schuind AE
Hum Vaccin Immunother; 2021 Nov; 17(11):4132-4143. PubMed ID: 34190658
[TBL] [Abstract][Full Text] [Related]
35. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
Giannelos N; Ng C; Curran D
Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
[TBL] [Abstract][Full Text] [Related]
37. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
[TBL] [Abstract][Full Text] [Related]
38. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
[TBL] [Abstract][Full Text] [Related]
39. The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
Strezova A; Lal H; Enweonye I; Campora L; Beukelaers P; Segall N; Heineman TC; Schuind AE; Oostvogels L
Vaccine; 2019 Sep; 37(39):5877-5885. PubMed ID: 31443993
[TBL] [Abstract][Full Text] [Related]
40. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM).
Pedrazzoli P; Lasagna A; Cassaniti I; Ferrari A; Bergami F; Silvestris N; Sapuppo E; Di Maio M; Cinieri S; Baldanti F
ESMO Open; 2022 Aug; 7(4):100548. PubMed ID: 35853350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
